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Abstract
Purpose Indoleamine 2,3-dioxygenase-1 (IDO1) and more recently, tryptophan 2,3-dioxygenase (TDO), are tryptophan-
catabolizing enzymes with immunoregulatory properties in cancer. IDO1 is more expressed than TDO in many tumours 
including melanomas; however, IDO inhibitors did not give expected results in clinical trials, highlighting the need to con-
sider TDO. We aimed to characterize both TDO expression and function in a melanoma cell line, named SK-Mel-28, with 
the purpose to compare it with a colon cancer cell line, HCT-8, and with a human endothelial cell line (HUVEC).
Methods TDO expression was assessed as real time-PCR and western blot, for mRNA and protein expression, respectively. 
While cell proliferation was assessed as cell duplication, cell apoptosis and cell cycle were analysed by means of flow 
cytometry.
Results SK-Mel-28 cells showed higher TDO levels compared to HCT-8 and to HUVEC cells. A selective TDO inhibitor, 
680C91, significantly impaired cell proliferation in a concentration-dependent manner, by inducing cell arrest during the 
G2 phase for SK-Mel-28 and HUVEC cells, while an early apoptosis was increasing in HCT-8 cells. No toxic effects were 
observed. These data demonstrated that TDO is highly expressed in SK-Mel-28 cells and may be involved in the regulation 
of their proliferation.
Conclusion TDO may directly modulate cancer cell function rather than immune suppression and can be considered as a 
target for melanoma progression together with IDO1.
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Introduction
Tryptophan (trp) degradation is a mechanism employed 
by a broad range of tumours to suppress the immune 
response. Two distinct enzymes are involved in its catab-
olism: indoleamine 2,3-dioxygenase (IDO1 and 2) and 
tryptophan 2,3-dioxygenase (TDO) that catalyse the first 
and rate limiting step of trp oxidation yielding kynurenine 
(kyn). The kynurenine pathway (KP) produces many bio-
logically active metabolites, including the redox oxidized 
cofactors nicotinamide adenine dinucleotide (phosphate) 
[NAD + (P +)] and its reduced form NAD(P)H. Many data 
are reported on IDO1 and immune escape. Overexpression 
of IDO1 gene contributes to the depletion of local trp and 
to the elevation of kyn in the tumour microenvironment that 
makes it immunosuppressive. T-cell and NK-cell are indeed 
sensitive to kyn accumulation that inhibits NK cell function, 
favours the differentiation of regulatory T lymphocytes (T 
reg) and suppresses proliferation and activity of effector T 
lymphocytes (Terness et al. 2002; Uyttenhove et al. 2003; 
Opitz et al. 2011). The sequence similarity between human 
IDO1 and TDO is low (16%), however maintaining a high 
similarity in their catalytic domains (Thackray et al. 2008). 
While TDO is specific for metabolizing tryptophan to kyn, 
IDO1 recognizes a broad range of indole-containing sub-
strates including the neurotransmitter melatonin. Moreo-
ver, they have different tissue distributions and physiologi-
cal roles; IDO is a monomeric enzyme less expressed in 
normal tissues and upregulated during inflammation, to 
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suppress immune reaction; TDO is a tetramer and it is highly 
expressed in the liver where it degrades excesses of dietary 
trp (Yu et al. 2017), in the placenta where it regulates the 
immune response (Yu et al. 2017), and in the brain where 
it regulates the synthesis of neurotransmitters (Beatty and 
Gladney 2015). TDO expression and its role within cancer 
has been poorly investigated until a few years ago, while 
the proven role of IDO in cancer biology has resulted in 
its extensive study and in the identification of pharmaco-
logical inhibitors. IDO1 is indeed upregulated in many 
solid tumours, contributes to immunologic evasion and it is 
associated with poor patient outcomes (Pilotte et al. 2012; 
Yu et al. 2018). Conversely, TDO2 mRNA expression has 
been found in some tumour cell lines and also in human 
tumours, such as hepatocarcinoma, melanoma and glioblas-
toma (van Baren and Van den Eynde 2015), cutaneous mela-
noma (Pilotte et al. 2012) and primary uveal melanoma, in 
which mRNA expression is generally low but its increase is 
associated with poor prognostic markers (Terai et al. 2020). 
TDO-mediated immunosuppression has been reported to 
be mediated by the human aryl hydrocarbon receptor (Ahr) 
(Platten et al. 2012). Its activation induces the activation of 
the Foxp3 in naïve T lymphocytes preventing the maturation 
of Th17 lymphocytes and a lower cell-mediated response, 
through the antigen presenting dendritic cells (DC), stimu-
lating the selective proliferation of Treg and therefore pro-
moting an immunosuppressive environment (Platten et al. 
2012). In addition, it has been demonstrated that in Ahr-
proficient mice the expression of TDO strongly enhanced 
tumour growth in comparison with tumours not expressing 
TDO (Opitz et al. 2011).
The importance of trp/kyn homeostasis in immune escape 
has made IDO1 and TDO good targets for the development 
of inhibitors. Despite promising results of some IDO1 inhib-
itors alone or in combination with PD1 inhibitors, their ben-
efits in melanoma patients have not been completely dem-
onstrated (Long et al. 2019). The expression and function of 
TDO in melanoma is not clear yet, and a further investiga-
tion is necessary.
Based on these considerations, we aimed to extend the 
knowledge of TDO expression and function. We evaluated 
the expression and the possible function of TDO in a human 
melanoma cell line, SK-Mel-28, in which TDO has never 
been characterized up to now, in a human colorectal cancer 
cell line HCT-8 and in human endothelial cells HUVEC.
Methods
Cell culture
A human metastatic melanoma cell line, SK-Mel-28 
(ATCC, Manassas, VA), a human colon adenocarcinoma 
cell line, HCT8, and HUVEC cells (ECACC, Salisbury 
UK) were grown on high D-glucose DMEM, RPMI and on 
M199, respectively. Media were supplemented with 10% 
(v/v) heat inactivated fetal bovine serum (FBS Defined 
Hyclone; Thermo Scientific, Waltman, MA), 100 U/mL 
penicillin, 100 μg/mL streptomycin and 2 mmol/L glu-
tamine in a humidified atmosphere with 5%  CO2 in air. 
The culture medium utilized, a “complete medium”, was 
changed every 2 days.
Real Time PCR
The total RNA was isolated from SK-Mel-28, HCT8 and 
HUVEC cells, using TRI Reagent and quantified spec-
troscopically with a NanoDrop (Thermo-fisher scientific, 
Waltham, Massachusetts, USA). One μg of RNA was used 
for the reverse transcription reaction with Prime Script 
RT reagent Kit with gDNA eraser (Takara, Otsu, Japan) 
and the cDNA samples obtained were amplified with spe-
cific primers described below. TDO2 amplification fw: 
5′-CTT ATC TCC AGC ATC AGG CTT CCA GAGT-3′ and 
rev: 5′-GGA GTT CTT TCC AGC CAT GCC TCC -3′.
Real-time PCR assays were carried out using SYBR 
Premix Ex Taq (Takara, Otsu, Japan) according to the 
manufacturer instructions on a Rotorgene RG-3000A cycle 
system (Qiagen, Germany) platform. PCR amplification 
of 18 s ribosomal mRNA was used as a normalizer. 18 s 
amplification fw: ATT AAG GGT GTG GGC CGA AG and 
rev: GGT GAT CAC ACG TTC CAC CT.
The cycle was set at 95 °C for 5 s, followed by 55 °C for 
30 s, repeated 35 times. Quantitative real-time polymerase 
chain reaction data analysis was accomplished with delta 
delta CT method.
Cell proliferation
Cell proliferation was quantified by total DNA/well via a 
fluorescent dye (cell proliferation kit, Invitrogen) (Paccosi 
et al. 2012). Briefly, cells (1.5 × 103/100 μl) were plated 
on flat-bottom 96-multiwell plates and allowed to adhere 
overnight. Cells were kept in starving conditions (1% FCS) 
for 24 h in the presence or absence of 680C91 (5–40 μM), 
then media were removed and replaced with 10% FCS 
medium. After 48 h, 100 μl of dye binding solution were 
added to each microplate well and incubated at 37 °C for 
30 min. Fluorescence intensity was read using a fluores-
cence microplate reader with excitation at ~ 485 nm and 
emission detection at ~ 530 nm.
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Cell cycle
Cell cycle analysis was performed by means of flow cytome-
try. Cells were starved for 24 h in 1% FCS in the presence or 
absence of 680C91 (20–40 μM). Then, they were harvested, 
washed in PBS and centrifuged at 280 g. Cellular pellets 
were fixed with 200 µl of 70% cold ethanol and incubated 
for 30 min in ice. After two washes and centrifuge at 850 g 
for 7 min, the pellet containing nucleic acid was incubated 
with 50 µl of a ribonuclease-A, 100 µg/ml solution, to digest 
RNA. After 30 min, cellular DNA was incubated with pro-
pidium iodide (PI) at a final concentration of 50 µg/ml. Cell 
cycle was measured with FACSCanto II™ flow cytometer 
(BD Biosciences, San Jose, CA) emitting at 488 nm, which 
provided PI excitation in the blue-to-green range which is 
related to DNA content in each phase of cell cycle. Histo-
grams of that emission were evaluated on linear scale with 
FCS express 6.0 software (De Novo Software, Pasadena, 
CA).
Cell apoptosis
Apoptosis was assessed by flow cytometry as previously 
reported (Grassia et al. 2010). Briefly, cells were starved 
in 1% FCS for 24 h in the presence or absence of 680C91 
(10–40 μM), then harvested and stained with FITC-annexin 
V and propidium iodide (PI) in PBS with  Ca2+ and  Mg2+ 
for 15 min in dark. Stained cells were immediately sub-
jected to flow cytometry analyses using FACS Canto II flow 
cytometer (BD Biosciences). Positive control was treated 
with 500 μM cumene hyroperoxide (CHPx) for 3 h before 
staining.
Western blot analysis
SK-Mel-28, HCT8 and HUVEC cells were lysed in a  Triton® 
X-100 lysis buffer, pH 7.4, followed by a centrifugation at 
14,000 rpm for 10 min at 4 °C (Paccosi et al. 2012). Cell 
lysate was run on 10% SDS–polyacrylamide gel electro-
phoresis, blotted onto PVDF membrane (Merk-Millipore, 
Darmstadt, Germany) and immunostained with mouse mon-
oclonal anti-TDO antibody (1:2000) and with anti β-tubulin 
monoclonal antibody (1:1000). The antigen–antibody com-
plexes were visualized using appropriate secondary antibod-




ribonuclease-A, CHPx, anti β-tubulin monoclonal anti-
body, TRI Reagent were from Merck (KGaA, Darmstadt, 
Germany); Annexin V was from ImmunoTools GmbH 
(Gladiolenweg 2; Germany); mouse monoclonal anti-TDO 
antibody was from NovusBio (Bio-Techne SRL, MI, Italy); 
propidium iodide (PI) (BD Biosciences); high D-glucose 
DMEM, RPMI 1640, M199 and PBS were from Euroclone 
S.p.A. (MI, Italy).
Statistical evaluation
Statistical analysis was performed with Prism software 
(GraphPad). Parametric data were reported as means ± SEM 
and differences between groups were tested with ANOVA 
test (followed by Bonferroni’s and Dunnett’s Multiple Com-
parison Test) as appropriate. Alpha value was set at 0.05.
Results
TDO expression
We investigated TDO expression as both mRNA (TDO2) 
and protein levels in SK-Mel-28, HCT-8 and HUVEC cells. 
TDO2 mRNA expression was significantly higher in SK-
Mel-28 cells, compared to the human colon adenocarcinoma 
cell line and to the human endothelium, being 4.8 ± 0.9 fold 
over HUVEC and 12.5 ± 5 over HCT-8 (Fig. 1a). Western 
blot in reducing conditions confirmed protein expression of 
a monomer of 49 kDa (Fig. 1b).
Effect of the selective TDO inhibitor 680C91 on cell 
proliferation
The effect of 680C91, a selective TDO inhibitor, on SK-
Mel-28, HCT8 and HUVEC cells growth was assessed. 
The addition of 680C91 (5–40 μM), significantly impaired 
cell proliferation in a concentration-dependent manner 
(Fig. 2b, c), whose maximal effect was observed at 40 μM, 
concentration capable to inhibit cell growth by 97.1 ± 2.3%, 
81.5 ± 0.5% and 65 ± 3.7%, for SK-Mel-28, HCT8 and 
HUVEC, respectively. At the highest concentration, (40 μM 
the TDO inhibitor did not affect basal proliferation and it 
was free of any toxic effect (data not shown).
Effect of the selective TDO inhibitor 680C91 on cell 
cycle
The analysis of the cell cycle phase distribution was per-
formed to deepen the antiproliferative effects observed in 
presence of the TDO inhibitor. The cell cycle phase distribu-
tion was analysed following a 24 h-treatment with 680C91 
at concentrations of 20 and 40 µM. Figure 3 shows that the 
percentage of SK-Mel-28 in the G2/M phase significantly 
decreased in a dose-dependent manner, compared to the 
unstimulated cells (the control cells), with a maximal effect 
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at 40 µM (− 79%). The decrease in the G2/M phase was 
accompanied by no significant differences in the G0 and S 
phases.
TDO inhibitor significantly impaired the cell cycle of 
HUVEC cells (Fig. 4), since a decrease of cell percentage 
in the G2/M phase was observed, at both concentrations 
(− 68%). Interestingly, we also observed a decrease in the S 
phase and an increase of the percentage of cells in the G0/G1 
phase. Conversely, 680C91 did not affect HCT8 cell cycle, 
as shown in Fig. 5.
Effect of 680C91 on cell apoptosis
To investigate whether TDO inhibition exerts its antiprolif-
erative activity via induction of apoptosis, cells were treated 
with varied doses of 680C91 and subjected to FITC-Annexin 
V/PI staining and analysis by a flow cytometer for measur-
ing early apoptosis (Fig. 6), late apoptosis and cell death 
(Table 1). Inhibition of TDO did not stimulate SK-Mel-28 
(Fig. 6a, d) nor HUVEC (Fig. 6c, f) apoptosis (early and 
late), nor cell death at any concentration tested (Table 1). 
Conversely, 680C91 significantly stimulated HCT-8 early 
apoptosis in a concentration dependent manner (Fig. 6b, e), 
with a maximal effect induced by 40 µM which induced 
apoptosis in 88.17 ± 0.88% of cells, comparable to the posi-
tive control (CHPx).
DISCUSSION
IDO and TDO are the main enzymes within the main path-
way of trp degradation, the kynurenine pathway (KP), which 
produces biologically active metabolites closely correlated 
with several diseases including inflammation diseases, dia-
betes, mental disorders, and cancer (Ye et al. 2019). It is 
known that trp catabolism mediated by IDO is an impor-
tant mechanism of peripheral immune tolerance contribut-
ing to the tumoral immune escape, so that IDO inhibition 
is an active area of drug development (Pilotte et al. 2012). 
Fig. 1  RT-PCR for TDO mRNA (TDO2, a) and protein (b) in 
HUVEC, HCT-8 and SK-Mel-28; Mean ± SEM, n = 4, *P < 0.001 vs 
HUVEC; ^P < 0.001 vs HCT-8
Fig. 2  Effect of the TDO inhibitor 680C31 on SK-Mel-28 (a) HCT-8 (b) and HUVEC proliferation (c). Mean ± SEM, n = 6; *P < 0.05 
**P < 0.01, ***P < 0.001 vs 10% FCS
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Despite promising results of IDO1 inhibitors in combina-
tion with checkpoint inhibitors, their benefits in melanoma 
patients have not been completely demonstrated (Kozlova 
and Frédérick 2019; Long et al. 2019). The latest phase 
III trial ECHO-301 have reported that the combination of 
epacadostat (IDO1 selective inhibitor) and PD-1 inhibitor 
Fig. 3  Effect of the TDO inhibi-
tor 680C31 (20 and 40 µM) 
on SK-Mel-28 cell cycle. 
Mean ± SEM, n = 3; **P < 0.01, 
vs control unstimulated cells 
(C). Cell cycle distribution of 
propidium iodide (PI)-labelled 
cells was analysed by flow cyto-
metric analyses. a G0/G1 phase; 
b S phase; c G2/M phase; d 
Close to bar graphs there is 
a representative histogram of 
control cells (grey line) and 
680C91-treated cells (red line)
Fig. 4  Effect of the TDO 
inhibitor 680C91 (20 and 
40 µM) on HUVEC cell cycle. 
Mean ± SEM, n = 3 **P < 0.01, 
vs control unstimulated cells 
(C). a G0/G1 phase; b S phase; 
c G2/M phase; d close to bar 
graphs there is a representative 
histogram of control cells (grey 
line) and 680C91-treated cells 
(red line)
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pembrolizumab did not provide any additional survival ben-
efit compared to pembrolizumab alone in advanced mela-
noma patients (Long et al. 2019). These findings indicate 
that IDO1-specific inhibitors cannot completely block the 
production of immunosuppressive trp catabolites involved 
in the immune escape, suggesting that TDO comes into play 
(Muller et al. 2019; Sari et al. 2019).
Although it has been shown that TDO has immunomod-
ulatory functions in promoting tumour immune resistance 
(Pantouris and Mowat 2014), however the role of TDO in 
human melanoma is still under investigation. This manu-
script shows, for the first time, that the human melanoma 
cell line SK-Mel-28 expresses TDO both on the mRNA 
(TDO2) and protein levels. Its functional characterization 
was compared with the one of a human ileocecal adeno-
carcinoma cell line (HCT-8) and with the one of human 
venular endothelial cells (HUVEC). IDO and TDO have an 
important physiological immune suppression role during 
pregnancy to avoid foetus rejection. HUVECs have been 
reported to express IDO1 (Beutelspacher et al. 2006) but 
no information is available for TDO. IDO1 has also been 
shown to be expressed in colorectal cancer (CRC) cell lines, 
and its expression at the tumour invasion front is involved 
in CRC progression (Ferdinande et al. 2012). No informa-
tion is reported for TDO expression and function in HCT-8 
cells. However, in a recent study, it has been found that TDO 
enzyme was elevated in 40% of the samples from colon can-
cer patients, while TDO2 mRNA was reduced in few colon 
cancer cells lines. Surprisingly, human colon cancer samples 
displayed a more robust up-regulation in the expression of 
trp transporters and enzymes in the kyn pathway, compared 
to the expression of the same samples evaluated in vitro, 
suggesting that this pathway is more active in vivo (Ven-
kateswaran et al. 2019). These findings could explain in 
our results the lesser amount of TDO2 mRNA expressed by 
HCT-8 cells, compared to the one of Sk-Mel-28 cells. How-
ever, the selective TDO inhibitor used, 680C91, confirmed 
that TDO is functional in HCT-8 cells.
TDO2 was highly expressed in the human melanoma 
cell line SK-Mel-28, which has never been reported until 
now. We then investigated its possible physiological role 
using a selective TDO inhibitor 680C91 (Salter and Pogson 
1985). Firstly, the block of TDO was assessed on cell pro-
liferation in optimal growth conditions (complete medium). 
The inhibition of TDO inhibited significantly and dose-
dependently the cell duplication with a maximal activity 
obtained with 40 μM. 680C91 was previously reported to 
reduce triple-negative breast cancer (TNBC) proliferation, 
migration, and invasion (D’Amato et al. 2015). Elevated 
TDO expression was indeed associated with an increased 
disease grade, an estrogenic receptor-negative status, and 
finally a shorter overall survival. The Authors also demon-
strated that pharmacologic inhibition or genetic knockdown 
of TDO increased sensitivity of TNBC cells to anoikis in a 
forced suspension culture.
To investigate the antiproliferative effect of 680C91 
more in detail, we assessed TDO inhibition both on cell 
cycle and cell apoptosis. Interestingly, antiproliferative 
Fig. 5  Effect of the TDO inhibi-
tor 680C91 (20 and 40 µM) on 
HCT-8 cell cycle. Mean ± SEM. 
a G0/G1 phase; b S phase; c 
G2/M phase; d close to bar 
graphs there is a representative 
histogram of control cells (grey 
line) and 680C91-treated cells 
(red line)
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mechanisms of 680C91 were different between cancer cell 
lines and HUVECs. Inhibition of SK-Mel-28 and HUVEC 
cell proliferation was due to cell cycle arrest in G2/M 
phase (Figs. 3 and 4) within 24 h. Conversely, 680C91 
did not affect cell cycle but promoted early apoptosis of 
HCT-8 cells. No cell death was observed, at least within 
24 h incubation with TDO inhibitor (Table 1). Therefore, 
inhibition of TDO has a dichotomous effect: pro-apoptotic 
Fig. 6  Effect of the TDO inhibitor 680C91 on SK-Mel-28 (a, d) 
HCT-8 (b, e) and HUVEC (c, f) apoptosis. a–c Bar chart show-
ing increased proportion of early apoptotic cells. Mean ± SEM, 
*P < 0.005, ***P < 0.001 vs control unstimulated cells (c). Positive 
control: CHPx, 500 μM d–f. Representative figures showing popula-
tion of viable (annexin  V−  PI−), early apoptotic (annexin  V+  PI−), late 
apoptotic (annexin  V+  PI+) and necrotic (annexin  V−  PI+) cells
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for HCT-8 cells and anti-proliferative for the endothelium 
and SK-Mel-28 cells.
There are some informations on the pro-angiogenic role 
of IDO in experimental models both in vivo and in vitro 
(Nonaka et al. 2011; Pan et al. 2017; Zhang et al. 2019). 
Furthermore, IDO1 has been suggested as a target in lung 
cancer since its expression is associated with the microves-
sel density (Pan et al. 2017). The inhibition of endothelial 
proliferation suggests that TDO may be involved in angio-
genesis. Recently, it has been discovered that some type of 
cancers (such as hepatocarcinoma, glioblastoma, bladder 
carcinoma) contained foci of non-tumoral TDO-expressing 
cells, which were identified as pericytes, that were found in 
high-grade tumours close to necrotic or hemorrhagic areas, 
characterized by neoangiogenesis (Hoffmann et al. 2020). 
Although these important observations on IDO1, no data are 
available on TDO and angiogenesis and on its cooperation 
with IDO1 on melanoma progression.
These data add new insights on TDO and cancer biol-
ogy since it may directly modulate cancer cell function and 
cancer microenvironment rather than immune suppression. 
Current researches on KP are actually focused on its immu-
nological function with very few studies on its role in the 
tumour microenvironment. Many studies have focused on 
IDO, while TDO data are almost completely missing. As 
previously reported by Optiz (2011), TDO/KP could be 
involved in cancer biology particularly when IDO does not 
account for the constitutive trp catabolism, such as in glioma 
brain tumours. In this study, it was demonstrated that TDO-
derived kyn suppresses antitumor immune responses and 
stimulates tumour-cell survival and migration through the 
AHR in an autocrine/paracrine fashion (Opitz et al. 2011).
It is mandatory that further investigations on the role of 
TDO in tumour biology and in particular in the progression 
of melanoma are needed to find new therapeutic strategies. 
Recently, an interesting study on the metabolomic identifi-
cation of human serum markers for advanced melanomas, 
pointed out that trp levels in metastatic patients were signifi-
cantly lower, at least 0.2 times than healthy human control 
samples. These data confirmed the importance of cellular 
metabolic processes as a hallmark of malignant transforma-
tion and or tumour progression (Bayci et al. 2018).
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